Design and synthesis of 3,5-dialkylamino substituted 8H,10H-3(R),5(R),15b(S)-2,3,6,7-tetrahydro-1,5,3-dioxazepino[3,2-c]indolo[3,2 -g]pteridine-7-ones

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 23, 1997, Pages 3023-3026

  Ge, Ping ^a   Kalman, Thomas I ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ELLIPTICINE; ELLIPTICINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG DESIGN; DRUG SYNTHESIS; IN VITRO STUDY; LEUKEMIA L 1210; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 0030662589     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10138-X     Document Type: Article

References (22)

1. (a) Ge, P. Ph.D. Dissertation, State University of New York at Buffalo, 1995; pp 134-141.
2. (b) Ge, P.; Voronin, G. O.; Kalman, T. I. Nucleosides Nucleotides 1996, 15, 1701.
3. (a) Neidle, S.; Abraham, Z. CRC Critical Rev. Biochem. 1984, 17, 73.
4. (b) Denny, W. A. Anti-Cancer Drug Design 1989, 4, 241.
5. (c) Baguley, B. C. Anti-Cancer Drug Design 1991, 6, 1.
6. (d) Fosse, P.; Rene, B.; Charra, M.; Paoletti, C.; Saucier, J. Mol. Pharmacol. 1992, 42, 590.
7. Auclair, C. Arch. Biochem. Biophys. 1987, 257, 1.
8. (a) Jasztold-Howorko, R.; Landras, C.; Pierre, A.; Atassi, G.; Guilbaud, N.; Kraus-Berthier, L.; Leonce, S.; Rolland, Y.; Prost, J.; Bisagni, E. J. Med Chem. 1994, 37, 2445.
9. (b) Ducrocq, C.; Wendling, F.; Tourbez-Perrin, M.; Rivalle, C.; Tambourin, P.; Pochon, F.; Bisagni, E. J. Med. Chem. 1980, 23, 1212.
10. (c) Larue, L.; Rivalle, C.; Muzard, G.; Paoletti, C.; Bisagni, E.; Paoletti, J. J. Med Chem. 1988, 31, 1951.
11. (d) Dari, A.; Christiaens, L. E.; Renson, M. J. Acta Chem. Scand 1993, 47, 208.
12. Le Peco, J. B.; Xuong, N. D.; Gosse, C.; Paoletti, C. Proc. Natl. Acad Sci., U.S.A. 1974, 71, 5078.
13. (a) Mucci-LoRusso, P.; Polin, L.; Biernat, L. A.; Valeriote, F. A.; Corbett, T. H. Invest. New Drugs 1990, 8, 253.
14. (b) Djiuric, Z.; Everett, C. K.; Valeriote, F. A. Cancer Res. 1992, 52, 1515.
15. (c) Khayat, D.; Borel, C.; Azab, M.; Paraisot, D.; Malaurie, E.; Bouloux, C.; Weil, M. Cancer Chemother. Pharmacol. 1992, 30, 226.
16. Ono, K.; Nakane, H.; Barre-Sinoussi, F.; Chermann, J. C. Cancer Lett. 1990, 51, 59.
17. Nguyen, C. H.; Lavelle, F.; Riou, J. F.; Bissery, M. C.; Huel, C.; Bisagni, E. Anti-Cancer Drug Design 1992, 7, 235.
18. (a) Riou, J.; Fosse, P.; Nguyen, C. H.; Larsen, A. K.; Bissery, M.; Grondard, L.; Saucier, J.; Bisagni, E.; Lavelle, F. Cancer Res. 1993, 53, 5987.
19. (c) Nabiev, I.; Chourpa, I.; Riou, J.; Nguyen, C. H.; Lavelle, F.; Manfait, M. Biochemistry 1994, 33, 9013.
20. Goldman, D.; Kalman, T. I. Nucleosides Nucleotides 1983, 2, 175.
21. 12
22. Mao, Z.; Pan, J.; Kalman, T. I. J. Med Chem. 1996, 39, 4340.